Endo to pay $192.7m to settle off-label promotion charges
This article was originally published in Scrip
Executive Summary
Under a settlement with the US Department of Justice (DOJ), Endo Pharmaceuticals, part of Endo Health Solutions, has agreed to pay $192.7m to resolve criminal and civil liability charges of marketing of its lidocaine patch Lidoderm in the US for uses not approved by the FDA.